Search Results

Equip your research team with expert-led GPCR pharmacology training. Used by discovery scientists across biotech, pharma, and academia. Shared pharmacology discipline for discovery teams. Corner lessons and analysis • Ability to suggest topics relevant to your programs • Access for biotech, pharma Expert-Level Mastery — Advanced Pharmacology Live AMA Sessions with Terry

Andrew Tobin draws from his experience leading translational GPCR programs and co-founding Keltic Pharma As co-founder and CEO of Keltic Pharma Therapeutics, he leads a biotechnology company developing a novel

Explore Martin Marro’s impact on GPCR drug discovery, assay innovation, and translational pharmacology bridging academia, pharma, and biotech. << Back to podcast list Strategic Partner(s) GPCR Assay Strategy Martin Marro, currently Executive Director and Head of Cell Pharmacology at Eli Lilly’s Obesity Research Marro’s career spans big pharma and biotech, encompassing functional assay development, GPCR internalization Scientists seeking practical advice on career pivots between academia, pharma, and biotech.

GPCR was created to break down barriers across academia, biotech, pharma, and CROs—so knowledge, tools including: Academic researchers (PI, postdoc, student) Industry scientists and R&D leaders Biotech and pharma

Evi Kostenis "Pharmacist by training - PhD in Pharmacology - Postdoc at the NIH with Dr. Juergen Wess - Postdoc and Group leader in Aventis, now Sanofi, Frankfurt, Germany - Head of in vitro Pharmacology at 7TM Pharma in Denmark; Full professor, department chair and director of the institute for pharmaceutical GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

GPCR Ecosystem, with the goal is to bring together GPCR scientists, biotech, and pharma leaders as well GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

Maria Waldhoer on why endpoint GPCR assays miss most of what ligands do — and what kinetic pharmacological Maria Waldhoer: Pharmacological Fingerprints and the Limits of Bias Dr. a driver of drug action AI combined with functional, not only structural, data The academic-to-Big-Pharma-to-biotech InterAx treats GPCR pharmacology the way engineers treat aircraft design: build the mathematical model Waldhoer, CSO of InterAx Biotech 02:19 — From zoology to GPCRs: fate, not choice 06:48 — Academia to Big Pharma

more than 25 years of experience in drug development. have been engaged in GPCR cellular and clinical pharmacology I have participated and initiated methodologies for development of pharmacologically active anti-GPCR have published or contributed in 38 published scientific work mainly in the field of immunology and pharmacology creation of Inoviem scientific in Nov. 2011 by myself we have been regularly working with GPCRs for our pharma GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

The vehicle by which Andrew is translating fundamental findings to commercial products is Keltic Pharma GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class analysis company supporting pharmaceutical, life science, and academic scientists in the development As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences

Prior to his role at Addgene, Jason held roles in academia, big pharma, and non-profit research organizations GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

of the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, Australia. In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. Pharmaceutical Industry Experiences and GPCR History Arthur shared his experiences in the pharmaceutical industry, highlighting the differences between big pharma and biotech. Arthur recounted a 2004 visit to a pharma company using replicates in assays.

Dmitry Veprintsev , a molecular pharmacologist at the University of Nottingham, to discuss his scientific Biotech – The unexpected journey into biotech entrepreneurship, providing GPCR profiling services to pharma Summary made with AI About Dmitry Veprintsev Dmitry is Professor of Molecular and Cellular Pharmacology at the Paul Scherrer Institute and ETH Zürich in Switzerland, changing his attention to structural pharmacology GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

list Strategic Partner(s) Inês Pinheiro, Monserrat Avila Zozaya & Yamina Berchiche About Inês Pinheiro PharmD As a young researcher fascinated by chemokine receptors, molecular pharmacology, drug discovery, and GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

Who should attend these GPCR pharmacology webinars? These webinars are ideal for: • GPCR pharmacologists • Medicinal chemists working on receptor targets The content is highly relevant for biotech and pharmaceutical scientists. Do I need prior knowledge of GPCR pharmacology? For researchers working in biotech, pharma, or academia, this type of continuing education can strengthen

Advance your GPCR research with expert-led Masterclasses on pharmacology, efficacy, signaling, and drug Sam Hoare Pharmechanics GPCR signaling & biased agonism expert regularly consulted by top pharma companies Pioneer in quantitative pharmacology methods. Dr. Yamina Berchiche Dr. Also super-valuable for those of us learning how to teach pharmacology GPCR researcher Dr. in academia, biotech, and pharmaceutical research.

covering effects on amino acid, lipid, and energy metabolism, with implications for glucagon-based pharmacotherapy ubiquitination, promoting foam cell formation. 🔒 Read Publication April 3, 2026 Lilly to acquire Centessa Pharmaceuticals C3aR1 in disease: From immunomodulation to cancer progression 🔒 Read Publication April 2, 2026 Zealand Pharma

Development department, leading her team on the development of innovative HTRF™ and AlphaLISA™ kits for pharma She has been leading collaborative projects with public research institutes and pharmaceutical companies HTRF technology and accelerate the company’s reagents use in academic labs, biotech companies, and pharma

Randy Hall Randy Hall, Ph.D., is a Professor of Pharmacology and Chemical Biology in the Emory University Randy has received a number of research prizes, including the PhRMA New Investigator Award, the Distinguished GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

industry-standard assays, designed for regulatory submissions, are backed by partnerships with leading pharma (MOA) cAMP accumulation β-Arrestin recruitment Receptor internalization Ligand binding Calcium flux Pharmaco These assays enable complete pharmacological profiling across cAMP, β-arrestin, and internalization. Together, these datasets exemplify the depth of pharmacological insight enabled by Eurofins DiscoverX

Who We Are We are a global network of scientists, biotech innovators, pharma professionals, CRO leaders fundraising or due diligence Expert Contributors Include: ✔ Terry Kenakin, with his exclusive series on GPCR pharmacology

Maria Waldhoer "I am a pharmacologist with a ~30 years background in academia and industry, working both in big pharma and biotech settings. Trejo joined the faculty in the Department of Pharmacology at the University of North Carolina in 2000 and then moved to UC San Diego School Medicine, Department of Pharmacology in 2008, where she quickly In 2014, she was appointed Vice-Chair of the Department of Pharmacology. The long-term goal of Dr.

in a competitive manner and in a short time (<3 months), customized fluorescent ligands with optimal pharmacological Maria Majellaro earned her degree in Pharmaceutical Chemistry and Technology from the University of Bari and completed her PhD in Biomolecular Sciences in Pharmacology and Medicine as “Doctor Europeus” in work focuses on organic synthesis, medicinal chemistry, and the development of GPCR-targeted tools for pharma Ligands in GPCR Research GPCRs are one of the most important families of therapeutic targets in the pharmaceutical

He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma equally focused on sex differences in pain processing and the failure of "one-size-fits-all" models in pharmacology Other academic interests of his include studying pharmaceutical finance & healthcare administration and GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

as a PhD project has grown into a commercial technology that helps scientists interrogate receptor pharmacology The company works with clients from pharma, CROs, and academia, including MD Anderson and several leading Maria Majellaro obtained her PhD with the distinction of Doctor Europeus from the Department of Pharmacy GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

She is also very active within the pharmacology community and currently serves on the editorial board of the British Journal of Pharmacology. Given her expertise in GPCR pharmacology and scientific communication, she is poised to make valuable Inês Pinheiro PharmD by training and Ph.D. candidate in Hartley's lab at the University of Geneva. Biology and Pharmacology from Monash University.

evolution of antibody engineering, with leadership roles at DIAX, Oncomed, Sutro Biopharma, and Lake Pharma GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses

accelerate your pipeline Book My Consultation Critical Bottlenecks in Your GPCR Pipeline ❌ Overwhelming pharmacology Actionable Scientific Validation: Ensure target companies execute the right GPCR pharmacology experiments Showcase your specialized GPCR expertise to stand out from competitors and attract high-value biotech and pharma Terry Kenakin, PhD UNC Chappel Hill In complex pharmacological discovery programs, scientific ambiguity Let’s talk about how I support GPCR discovery, pharmacology strategy, and cross-functional execution

Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. Scientific Themes of the Conversation Cellular Context as the Missing Variable — Why receptor pharmacology Hebert argues this was not a failure of the concept but of incomplete pharmacological characterization Patient-Derived iPSCs Open the Door to Personalized GPCR Pharmacology Dr. iPSC-derived models, and patient-specific cells 18:44 Industry partnerships and the path from bench to pharma